10-Q · May 5, 2026
Q32 Bio reported a net loss of $7.6 million in Q1 2026, improving from a loss of $11.0 million year-over-year, indicating a positive trend in financial performance. The company has maintained a strong cash position with…
Earnings analysis · 10-Q
QTTB earnings analysis
Filed August 5, 2026 · Our reading of the company's report
The latest report
Q32 Bio reported no product revenue and a Q2 2026 loss per share of $0.44, with net loss narrowing by $0.543 million year over year to $8.946 million. Cash burn improved substantially, and cash of $106.3 million at…
Read full summary
Q32 Bio reported no product revenue and a Q2 2026 loss per share of $0.44, with net loss narrowing by $0.543 million year over year to $8.946 million. Cash burn improved substantially, and cash of $106.3 million at quarter-end was supplemented by $187.6 million of net July follow-on proceeds, while venture debt of approximately $6.8 million was repaid. The central investment catalyst is bempikibart: Week 36 Part B data showed a 35.3% mean SALT reduction in the 25-patient mITT set, but the company remains dependent on regulatory alignment, later-stage trial execution, and future capital beyond its stated Phase 3 topline runway.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.44
What stood out
-
Quarterly loss narrowed modestly
Q2 net loss narrowed to $8.946 million from $9.489 million a year earlier, while reported loss per share was $0.44. Operating loss improved modestly to $9.118 million from $9.171 million.
-
Operating cash burn improved sharply
Six-month operating cash use fell 59.3% to $9.418 million from $23.133 million. The improvement reflected lower operating expenses and favorable working-capital movements, including a $3.4 million decrease in prepaid expenses.
-
Liquidity strengthened and debt retired
Cash and cash equivalents were $106.3 million at June 30, 2026; subsequent to quarter-end, the company raised $187.6 million net in its July follow-on financing. It also retired approximately $6.8 million of venture debt on June 24.
-
Bempikibart showed Week 36 clinical activity
Bempikibart's SIGNAL-AA Part B reported a 35.3% mean reduction in SALT score at Week 36 in the mITT population; 40.0% (10 of 25) achieved SALT20 and 44.0% (11 of 25) achieved SALT50.
-
R&D base declined despite lead-program investment
R&D expense declined to $4.259 million from $5.161 million year over year, principally because ADX-097 expense fell by $0.914 million after its sale. This more than offset a $0.601 million increase in bempikibart spending.
-
Pipeline now concentrated on bempikibart
The company had no product sales and no reportable revenue segments. Bempikibart direct R&D spending increased to $2.408 million from $1.807 million, while ADX-097 spending was eliminated following the November 2025 asset sale.
What to watch
-
Additional funding remains necessary
The company remains pre-revenue and had an accumulated deficit of $221.5 million as of June 30, 2026. It states that its cash balance plus subsequent financing proceeds will not be sufficient to advance programs through regulatory approval and that additional capital will be required.
-
Substantial equity dilution from financings
Financing materially increased the share base: the July offering sold 6,027,399 common shares plus pre-funded warrants for 4,931,506 shares, generating $187.6 million net. The May private placement added 6,725,000 shares and warrants for 150,000 shares for $53.4 million net.
-
BIOSECURE-related vendor disruption risk
A newly emphasized supply-chain risk is the BIOSECURE Act (Section 851 of the FY2026 NDAA, enacted December 18, 2025). The company uses foreign CROs/CDMOs including WuXi Biologics; a future designation could require supplier transitions, delaying development and increasing costs.
-
Clinical evidence remains early and limited
The lead efficacy dataset is an open-label study of 33 enrolled patients, with the primary mITT analysis based on 25 patients. Management still needs regulatory discussions before beginning a registration-directed program in the first half of 2027.
-
G&A inflation offsets some cost savings
Quarterly G&A expense rose $0.849 million to $4.859 million, driven by higher stock compensation and other operating costs. This partly offset the $0.902 million reduction in R&D expense.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. Management continues to expect to initiate a registration-directed bempikibart program in the first half of 2027 following regulatory discussions later in 2026, and expects June 30 cash plus the July financing proceeds to fund operations through planned Phase 3 topline results.
Earlier filings 4
10-K · March 10, 2026
QTTB’s 2025 10-K shows a repositioning toward clinical advancement of bempikibart (ADX-914) after a corporate restructuring and the sale of ADX-097 assets. The company completed enrollment in SIGNAL‑AA Part B (33…
10-Q · November 13, 2025
Q32 Bio reported a materially smaller quarterly loss: net loss of $7.389 million (Q3 2025) vs $17.595 million (Q3 2024) and EPS of $(0.60) vs $(1.46) a year earlier. Operating expenses fell to $7.577 million in the…
10-Q · August 6, 2025
Q32 Bio reported no revenue and a Q2 net loss of $9,489 (amounts per filing) versus $16,978 in Q2 2024, improving EPS to $(0.78) from $(1.42). Operating expenses were sharply reduced (total operating expenses down to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.